|
186 Companies |
|
244 Products |
|
244 Products |
|
91 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12345678910111213...5253» |
- | Jakafi (ruxolitinib) / Incyte, Farydak (panobinostat) / Secura Bio
Trial completion date, Trial primary completion date, Epigenetic controller: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (clinicaltrials.gov) - Feb 13, 2018
P1/2, N=18, Active, not recruiting, Sponsor: John Mascarenhas
Trial primary completion date: Dec 2017 --> Feb 2019 | Trial completion date: Dec 2017 --> Feb 2019
- azacitidine / Generic mfg.
Enrollment closed, Trial primary completion date, Combination therapy: A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (clinicaltrials.gov) - Feb 12, 2018
P1, N=36, Active, not recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Trial primary completion date: Dec 2017 --> Feb 2019 | Trial completion date: Dec 2017 --> Feb 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jan 2018
- Jakafi (ruxolitinib) / Incyte
Trial completion date, Trial primary completion date: Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Feb 8, 2018
P1, N=31, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jan 2018 Trial primary completion date: Feb 2019 --> Feb 2020 | Trial completion date: Feb 2019 --> Feb 2021
- | Promacta (eltrombopag) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) (clinicaltrials.gov) - Feb 5, 2018
P2/3, N=116, Recruiting, Sponsor: B. H
Trial primary completion date: Feb 2019 --> Feb 2020 | Trial completion date: Feb 2019 --> Feb 2021 Trial primary completion date: Sep 2020 --> Sep 2022 | Trial completion date: Sep 2021 --> Sep 2023 | Initiation date: Mar 2015 --> Jan 2015
- | Besremi (ropeginterferon alfa-2b) / PharmaEssentia, AOP Orphan Pharma
Trial completion: PEGINVERA: Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (clinicaltrials.gov) - Jan 30, 2018
P1/2, N=24, Completed, Sponsor: AOP Orphan Pharmaceuticals AG
Trial primary completion date: Sep 2020 --> Sep 2022 | Trial completion date: Sep 2021 --> Sep 2023 | Initiation date: Mar 2015 --> Jan 2015 Active, not recruiting --> Completed
- | Enrollment closed, Enrollment change: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jan 30, 2018
P1, N=20, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=40 --> 20
- | Trial completion: Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=36, Completed, Sponsor: The Cleveland Clinic
Recruiting --> Active, not recruiting | N=40 --> 20 Active, not recruiting --> Completed
- Amevive (alefacept) / Astellas
Enrollment change, Trial termination, Trial primary completion date: Alefacept in Patients With Relapsed/Refractory Aplastic Anemia (clinicaltrials.gov) - Jan 26, 2018
P1/2, N=4, Terminated, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed N=56 --> 4 | Suspended --> Terminated | Trial primary completion date: Nov 2017 --> Dec 2011; Study drug not available at this time
- | Trial completion: Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=27, Completed, Sponsor: University of British Columbia
N=56 --> 4 | Suspended --> Terminated | Trial primary completion date: Nov 2017 --> Dec 2011; Study drug not available at this time Recruiting --> Completed
- ||||||| Pegasys (pegylated interferon α -2a) / Roche
Trial completion: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) (clinicaltrials.gov) - Jan 24, 2018
P3, N=168, Completed, Sponsor: Ronald Hoffman
Recruiting --> Completed Active, not recruiting --> Completed
- | Loargys (pegzilarginase) / Immedica
Trial completion, Enrollment change: A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS (clinicaltrials.gov) - Jan 24, 2018
P1, N=29, Completed, Sponsor: Aeglea Biotherapeutics
Active, not recruiting --> Completed Recruiting --> Completed | N=58 --> 29
- | atorvastatin / Generic mfg.
Trial completion, Trial primary completion date: Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jan 23, 2018
P2, N=40, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Completed | N=58 --> 29 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2014
- | Enrollment change, Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Jan 19, 2018
P=N/A, N=131, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2014 N=571 --> 131 | Trial primary completion date: Sep 2016 --> Jun 2016
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial completion, Trial primary completion date: A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Jan 17, 2018
P1, N=47, Completed, Sponsor: Weill Medical College of Cornell University
N=571 --> 131 | Trial primary completion date: Sep 2016 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2014
- | cyclophosphamide / Generic mfg.
Trial completion, Post-transplantation: Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT (clinicaltrials.gov) - Jan 16, 2018
P2, N=200, Completed, Sponsor: Ivan S Moiseev
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2014 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 12, 2018
P1/2, N=52, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2016
- | Trial primary completion date: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 11, 2018
P1, N=30, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2016 Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial primary completion date: AMC-HEMREG-CML: Chronic Myelod Leukemia Registry at Asan Medical Center (clinicaltrials.gov) - Jan 10, 2018
P=N/A, N=100, Terminated, Sponsor: Asan Medical Center
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2047 --> May 2016
- vadastuximab talirine (SGN-CD33A) / Pfizer
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS (clinicaltrials.gov) - Jan 5, 2018
P1/2, N=19, Terminated, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Dec 2047 --> May 2016 N=142 --> 19 | Suspended --> Terminated | Trial primary completion date: May 2019 --> Nov 2017; Sponsor decision based on portfolio prioritization
- | Trial completion, Enrollment change, Trial primary completion date: Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (clinicaltrials.gov) - Jan 4, 2018
P=N/A, N=571, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
N=142 --> 19 | Suspended --> Terminated | Trial primary completion date: May 2019 --> Nov 2017; Sponsor decision based on portfolio prioritization Recruiting --> Completed | N=400 --> 571 | Trial primary completion date: Dec 2018 --> Sep 2016
- lenalidomide / Generic mfg., azacitidine / Generic mfg.
Trial primary completion date: LEN-MEC: Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS (clinicaltrials.gov) - Jan 3, 2018
P2, N=33, Terminated, Sponsor: Stanford University
Recruiting --> Completed | N=400 --> 571 | Trial primary completion date: Dec 2018 --> Sep 2016 Trial primary completion date: Aug 2014 --> Mar 2014
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination: Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease (clinicaltrials.gov) - Dec 28, 2017
P2, N=24, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Aug 2014 --> Mar 2014 Completed --> Terminated
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment closed: A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Dec 26, 2017
P1, N=47, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Completed --> Terminated Terminated --> Active, not recruiting
- ||||||| Jakafi (ruxolitinib) / Incyte
Trial completion, Phase classification: INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (clinicaltrials.gov) - Dec 21, 2017
P3, N=2232, Completed, Sponsor: Novartis Pharmaceuticals
Terminated --> Active, not recruiting No Longer Available --> Completed | Phase classification: P4 --> P3
- |||||||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
New P3 trial: Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Dec 20, 2017
P3, N=147, Completed, Sponsor: Amgen
- ||||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion: Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Dec 20, 2017
P3, N=147, Completed, Sponsor: Amgen
No Longer Available --> Completed | Phase classification: P4 --> P3 Active, not recruiting --> Completed
- | Phase classification: Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels (clinicaltrials.gov) - Dec 20, 2017
P=N/A, N=397, Active, not recruiting, Sponsor: Medtronic Spinal and Biologics
Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
- | Trial completion, Enrollment change, Trial primary completion date: Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=16, Completed, Sponsor: Case Comprehensive Cancer Center
Phase classification: P3 --> P=N/A Recruiting --> Completed | N=45 --> 16 | Trial primary completion date: Jun 2017 --> Sep 2017 | Recruiting --> Completed | N=45 --> 16 | Trial primary completion date: Jun 2017 --> Sep 2017 | Recruiting --> Completed | N=45 --> 16 | Trial primary completion date: Jun 2017 --> Sep 2017
- | lenalidomide / Generic mfg., azacitidine / Generic mfg.
Trial completion, Trial primary completion date: Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q (clinicaltrials.gov) - Dec 15, 2017
P2, N=50, Completed, Sponsor: Groupe Francophone des Myelodysplasies
Recruiting --> Completed | N=45 --> 16 | Trial primary completion date: Jun 2017 --> Sep 2017 | Recruiting --> Completed | N=45 --> 16 | Trial primary completion date: Jun 2017 --> Sep 2017 | Recruiting --> Completed | N=45 --> 16 | Trial primary completion date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Jul 2016
- | Enrollment closed: Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=3000, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Jul 2016 Recruiting --> Active, not recruiting
- | Promacta (eltrombopag) / Novartis
Trial initiation date, Trial termination, Combination therapy: A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Dec 12, 2017
P3, N=356, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Feb 2010 --> Jun 2014 | Completed --> Terminated
- | Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment change, Trial termination, Trial primary completion date: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 5, 2017
P1, N=1, Terminated, Sponsor: Bruno C. Medeiros
Initiation date: Feb 2010 --> Jun 2014 | Completed --> Terminated N=19 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2015; logistics
- | mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial primary completion date: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Dec 5, 2017
P1, N=16, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=19 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2015; logistics Trial primary completion date: Dec 2016 --> Dec 2017
- | Trial completion, Stroma: Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers (clinicaltrials.gov) - Dec 4, 2017
P=N/A, N=35, Completed, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Dec 2016 --> Dec 2017 Terminated --> Completed
- volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial primary completion date, Combination therapy: Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML (clinicaltrials.gov) - Nov 30, 2017
P1, N=16, Terminated, Sponsor: Boehringer Ingelheim
Terminated --> Completed Trial primary completion date: Jun 2018 --> Dec 2016
- Erivedge (vismodegib) / Roche
Phase classification, Enrollment change, Trial termination, Trial primary completion date, Combination therapy: A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) (clinicaltrials.gov) - Nov 27, 2017
P1, N=10, Terminated, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2018 --> Dec 2016 Phase classification: P1/2 --> P1 | N=104 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Mar 2017
- | imatinib / Generic mfg.
Trial completion: A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML (clinicaltrials.gov) - Nov 24, 2017
P2, N=139, Completed, Sponsor: Versailles Hospital
Phase classification: P1/2 --> P1 | N=104 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Mar 2017 Active, not recruiting --> Completed
- | Rydapt (midostaurin) / Novartis
Enrollment open, Combination therapy: Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 20, 2017
P2, N=36, Recruiting, Sponsor: Bruno C. Medeiros
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion, Enrollment change, Trial primary completion date: Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia (clinicaltrials.gov) - Nov 14, 2017
P1/2, N=5, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=94 --> 5 | Trial primary completion date: Feb 2019 --> Nov 2017
- | RG6146 / Roche
Trial completion, Enrollment change, Trial primary completion date: A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 14, 2017
P1, N=26, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=94 --> 5 | Trial primary completion date: Feb 2019 --> Nov 2017 Recruiting --> Completed | N=51 --> 26 | Trial primary completion date: Jan 2018 --> Aug 2017
- | Trial completion, Enrollment change, Trial primary completion date: PEG-MF: Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=62, Completed, Sponsor: University Hospital, Brest
Recruiting --> Completed | N=51 --> 26 | Trial primary completion date: Jan 2018 --> Aug 2017 Recruiting --> Completed | N=100 --> 62 | Trial primary completion date: Sep 2017 --> Jan 2017
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial termination, Trial primary completion date: Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis (clinicaltrials.gov) - Nov 6, 2017
P2, N=6, Terminated, Sponsor: Weill Medical College of Cornell University
Recruiting --> Completed | N=100 --> 62 | Trial primary completion date: Sep 2017 --> Jan 2017 Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jun 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jun 2017; This study was suspended due to insufficient subject accrual.
- | Phase classification: Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy (clinicaltrials.gov) - Nov 1, 2017
P=N/A, N=321, Completed, Sponsor: AOSpine North America Research Network
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jun 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jun 2017; This study was suspended due to insufficient subject accrual. Phase classification: P4 --> P=N/A
- | mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial primary completion date: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Oct 25, 2017
P1, N=16, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Phase classification: P4 --> P=N/A Trial primary completion date: Sep 2016 --> Dec 2016
- | Enrollment change, Trial termination: Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Oct 23, 2017
P=N/A, N=56, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2016 --> Dec 2016 N=500 --> 56 | Recruiting --> Terminated; A replacement protocol was created to replace this current version of protocol.
- | Trial primary completion date: PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
N=500 --> 56 | Recruiting --> Terminated; A replacement protocol was created to replace this current version of protocol. Trial primary completion date: Sep 2017 --> Dec 2017
- | adavosertib (AZD1775) / AstraZeneca, Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment closed, Combination therapy: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 13, 2017
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2017 --> Dec 2017 Suspended --> Active, not recruiting
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Phase classification, Metastases: Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Oct 12, 2017
P1, N=7, Completed, Sponsor: University of California, San Francisco
Suspended --> Active, not recruiting Phase classification: P=N/A --> P1
- | Trial completion, Enrollment change, Trial primary completion date: Hypofractionated Radiotherapy (16/2) for the Palliation of Complicated Bone Metastases in Patients With KPS (clinicaltrials.gov) - Oct 6, 2017
P2, N=50, Completed, Sponsor: Santa Casa de Porto Alegre
Phase classification: P=N/A --> P1 Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Dec 2015 --> Jul 2016
- | cyclosporine / Generic mfg.
Trial completion: The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers (clinicaltrials.gov) - Oct 5, 2017
P2, N=102, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | N=100 --> 50 | Trial primary completion date: Dec 2015 --> Jul 2016 Active, not recruiting --> Completed